Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration

Molecular Pharmacology

Volumn 63, Issue 1, 2003, Pages 96-104

  Schoedel, Kerri A ^a   Sellers, Edward M ^a,b   Palmour, Roberta ^c   Tyndale, Rachel F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; MESSENGER RNA; NICOTINE; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CERCOPITHECIDAE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; IMMUNOBLOTTING; LIVER METABOLISM; LONG TERM EXPOSURE; MALE; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; XENOBIOTIC METABOLISM;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CERCOPITHECUS AETHIOPS; DOWN-REGULATION; HEPATOCYTES; MALE; MIXED FUNCTION OXYGENASES; MODELS, ANIMAL; NICOTINE; NICOTINIC AGONISTS; RNA, MESSENGER; SMOKING;

EID: 0037222167     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.1.96     Document Type: Article

References (43)

1. Baron JA (1996) Beneficial effects of nicotine and cigarette smoking: The real, the possible and the spurious. Br Med Bull 52:58-73.
2. Benowitz NL (1988) Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 319:1318-1330.
3. Benowitz NL, Griffin C, and Tyndale R (2001) Deficient C-oxidation of nicotine continued. Clin Pharmacol Ther 70:567.
4. Benowitz NL and Jacob P 3rd (1993) Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther 53:316-323.
5. Benowitz NL and Jacob P 3rd (2000) Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 67:653-659.
6. Benowitz NL, Jacob P 3rd, Fong I, and Gupta S (1994) Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268:296-303.
7. Benowitz NL, Porchet H, and Jacob P 3rd (1989) Nicotine dependence and tolerance in man: Pharmacokinetic and pharmacodynamic investigations. Prog Brain Res 79:279-287.
8. Benowitz NL, Zevin S, and Jacob P 3rd (1997) Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine and cigarette smoking. Br J Clin Pharmacol 43:259-267.
9. Bourrie M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
10. Chang TK, Gonzalez FJ, and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
11. Eagling VA, Tjia JF, and Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114.
12. Howard LA, Micu AL, Sellers EM, and Tyndale RF (2001) Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J Pharmacol Exp Ther 299:542-550.
13. Iba MM, Fung J, Pak YW, Thomas PE, Fisher H, Sekowski A, Halladay AK, and Wagner GC (1999) Dose-dependent up-regulation of rat pulmonary, renal and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding. Drug Metab Dispos 27:977-982.
14. Igarashi T, Sakuma T, Isogai M, Nagata R, and Kamataki T (1997) Marmoset liver cytochrome P450s: Study for expression and molecular cloning of their cDNAs. Arch Biochem Biophys 339:85-91.
15. Karnath B (2002) Smoking cessation. Am J Med 112:399-405.
16. Kyerematen GA, Damiano MD, Dvorchik BH, and Vesell ES (1982) Smoking-induced changes in nicotine disposition: Application of a new HPLC assay for nicotine and its metabolites. Clin Pharmacol Ther 32:769-780.
17. Kyerematen GA, Morgan ML, Chattopadhyay B, deBethizy JD, and Vesell ES (1990) Disposition of nicotine and eight metabolites in smokers and nonsmokers: Identification in smokers of two metabolites that are longer lived than cotinine. Clin Pharmacol Ther 48:641-651.
18. Kyerematen GA, Taylor LH, deBethizy JD, and Vesell ES (1988) Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos 16:125-129.
19. Lee BL, Benowitz NL, and Jacob P 3rd (1987) Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin Pharmacol Ther 41:474-479.
20. Li Y, Li NY, and Sellers EM (1997) Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur J Drug Metab Pharmacokinet 22:295-304.
21. McMorrow MJ and Foxx RM (1983) Nicotine's role in smoking: An analysis of nicotine regulation. Psychol Bull 93:302-327.
22. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
23. Miksys S, Hoffmann E, and Tyndale RF (2000) Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 59:1501-1511.
24. Miller LG (1990) Cigarettes and drug therapy: Pharmacokinetic and pharmacodynamic considerations. Clin Pharm 9:125-135.
25. Murayama N, Sai K, Nakajima Y, Kaniwa N, Ozawa S, Ohno Y, and Sawada J (2001) Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res 92:524-528.
26. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, and Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217.
27. Nakayama H, Okuda H, Nakashima T, Imaoka S, and Funae Y (1993) Nicotine metabolism by rat hepatic cytochrome P450s. Biochem Pharmacol 45:2554-2556.
28. Ohmori S, Horie T, Guengerich FP, Kiuchi M, and Kitada M (1993) Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Arch Biochem Biophys 305:405-413.
29. Ohmori S, Sakamoto Y, Nakasa H, and Kitada M (1998) Nucleotide and amino acid sequences of the monkey P450 2B gene subfamily. Res Commun Mol Pathol Pharmacol 99:17-22.
30. Pearce R, Greenway D, and Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol and testosterone oxidation. Arch Biochem Biophys 298:211-225.
31. Pelkonen O, Rautio A, Raunio H, and Pasanen M (2000) CYP2A6: A human coumarin 7-hydroxylase. Toxicology 144:139-147.
32. Poland RE, Pechnick RN, Cloak CC, Wan YJ, Nuccio I, and Lin KM (2000) Effect of cigarette smoking on coumarin metabolism in humans. Nicotine Tob Res 2:351-354.
33. Ramamoorthy Y, Tyndale RF, and Sellers EM (2001) Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
34. Rotenberg KS and Adir J (1983) Pharmacokinetics of nicotine in rats after multiplecigarette smoke exposure. Toxicol Appl Pharmacol 69:1-11.
35. Seaton M, Kyerematen GA, Morgan M, Jeszenka EV, and Vesell ES (1991) Nicotine metabolism in stumptailed macaques, Macaca arctoides. Drug Metab Dispos 19:946-954.
36. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, and Wrighton SA (1995) Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metab Dispos 23:1231-1241.
37. Stalhandske T and Slanina P (1970) Effect of nicotine treatment on the metabolism of nicotine in the mouse liver in vitro. Acta Pharmacol Toxicol 28:75-80.
38. Tiano HF, Wang RL, Hosokawa M, Crespi C, Tindall KR, and Langenbach R (1994) Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 15:2859-2866.
39. Tyndale RF and Sellers EM (2001) Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 29:548-552.
40. Yamazaki H, Inoue K, Hashimoto M, and Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73:65-70.
41. Yanev S, Kent UM, Pandova B, and Hollenberg PF (1999) Selective mechanismbased inactivation of cytochromes P-450 2B1 and P-450 2B6 by a series of xanthates. Drug Metab Dispos 27:600-604.
42. Zevin S, Jacob P 3rd and Benowitz N (1997) Cotinine effects on nicotine metabolism. Clin Pharmacol Ther 61:649-654.
43. Zhang W, Kilicarslan T, Tyndale RF, and Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897-902.